- Trial phase
- Phase 3 (Filed/PDUFA pending)
- Time to market
- The BLA was submitted to the FDA on October 27, 2026. If accepted for filing, a standard review would target a PDUFA decision roughly 10 months from the filing date (approximately August-September 2027). If priority review is granted, the timeline would be approximately 6 months (approximately April-May 2027).
- Why 4/10
- The BLA was submitted to the FDA on October 27, 2026, just three days ago. The next hard catalyst is FDA acceptance of the filing (expected ~60 days, so late December 2026), which would then set a PDUFA date. With AbbVie's ~$519 billion market cap and diversified portfolio spanning immunology, neuroscience, and oncology, etentamig is a meaningful pipeline asset but not a company-defining product. Even a binary PDUFA outcome would move the stock only modestly.
The next catalyst is FDA acceptance of the BLA for filing, expected roughly 60 days from the October 27 submission (late December 2026). If accepted, a PDUFA date will be set: roughly 6 months from filing if priority review is granted, or 10 months for standard review. Watch for whether the FDA grants priority review, which would shorten the timeline and signal regulatory enthusiasm. Also watch for European filing plans and potential partnership/commercialization strategy updates from AbbVie.
Price Chart
Executive Summary
Etentamig (ABBV-383) is AbbVie's second-generation BCMA x CD3 bispecific T-cell engager for relapsed/refractory multiple myeloma. The Phase 3 CERVINO trial met both primary endpoints with a 74.0% objective response rate versus 45.7% for standard therapies and a 60% reduction in the risk of progression or death (PFS HR 0.40). AbbVie submitted a BLA to the FDA on October 27, 2026, just three days ago. The drug would enter a competitive market already containing three approved BCMA bispecifics (J&J's Tecvayli, Pfizer's Elrexfio, Regeneron's Linvoseltamab). For AbbVie, a $519 billion diversified pharma company, etentamig is a meaningful pipeline asset but not a company-defining product.
How It Works
Etentamig is a bispecific antibody, a type of engineered immune protein that grabs two targets at once. One arm binds to CD3 receptors on T-cells (the immune system's killer cells), and the other arm binds to BCMA, a protein found on the surface of multiple myeloma cancer cells. This brings T-cells and cancer cells together, triggering the T-cells to attack and destroy the myeloma cells. It is a "second-generation" version designed with a weaker CD3 grip to reduce side effects like cytokine release syndrome, and with a longer half-life that allows monthly intravenous dosing after a single step-up dose.
Trial Status
The Phase 3 CERVINO trial (NCT06158841) enrolled 393 patients with triple-class exposed relapsed/refractory multiple myeloma who had received a median of three prior lines of therapy. At a median follow-up of 11.4 months, etentamig met both primary endpoints: objective response rate of 74.0% versus 45.7% for standard available therapies (p<0.0001), and a 60% reduction in the risk of progression or death (PFS hazard ratio 0.40, p<0.0001). The 12-month overall survival rate was 87.9% for etentamig versus 72.0% for standard therapy, though the pre-specified efficacy boundary for OS was not crossed at data cutoff. Cytokine release syndrome occurred in 28.3% of patients (mostly grade 1, no grade 3 or higher). Treatment discontinuation due to adverse events was lower for etentamig (3.6% vs 9.6%). Full results were presented at the International Myeloma Society Annual Meeting in September 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA acceptance of BLA filing (expected ~60 days from Oct 27, 2026, so late December 2026)
- Grant or denial of priority review designation
- PDUFA target action date (to be set upon filing acceptance)
- Potential European Medicines Agency filing
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report